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Abstract
Background: The role of the surface capsular polysaccharides (CPs) of Mycobacterium tuberculosis (Mtb) in the
pathogenesis of infection and disease, as well their potential for use as diagnostic reagents and vaccine antigens,
are unknown.
Methods: Serum antibody to two CPs of Mtb, arabinomannan (AM) and glucan (Glu), were studied in samples from
52 18–74 year-old HIV-seronegative, immunocompetent individuals in Houston Texas. The effects of Mtb exposure,
infection and disease upon the levels of antibodies to these CPs were assessed. Subjects were grouped according
to the standard international classification.
Results: IgA anti-Glu levels were significantly higher in the active and treated TB compared to a group that was
PPD-negative without TB exposure history (p<0.05). Antibodies against AM demonstrated a similar pattern, with the
exception that IgG anti-AM was higher in groups who had active TB or previously documented active TB, and IgA
anti-AM was higher in subjects with previously documented active TB compared to the level in an unexposed,
PPD-negative group (p<0.05). Serum IgG anti-Glu levels were higher in subjects with active TB or previously
documented active TB than in the unexposed PPD-negative group, but the differences were not significant.
Conclusions: These data suggest that the evaluation of antibody responses to the CP of Mtb may have utility for
TB serodiagnosis, and that vaccines designed to induce humoral responses to TB CPs should be tested for their
capacity to evoke anti-tuberculosis protective immunity.
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Background
Despite the availability of chemotherapeutic agents and
a vaccine (BCG), Mtb remains the number one cause of
death due to bacterial infectious diseases worldwide. In
2011, 8.7 million people developed clinical disease and
1.4 million died from TB [1]. Control of TB has been
hampered by the absence of sensitive diagnostic means,
the spread of HIV infection, and the emergence of
multidrug resistant Mtb. The only licensed vaccine
against tuberculosis (BCG) is effective in preventing
systemic TB in children, but its efficacy against pulmo-
nary TB in adults is controversial [2]. Improved vaccines
and diagnostic assays are needed.
Mtb is an encapsulated organism and its capsule is
composed of lipid derivatives of arabinomann (AM) and
glucan (Glu) [3-6]. The role of these CPs in pathoge-
nesis of and immunity to Mtb is unknown; however,
CPs of other important bacteria such as Haemophilus
influenzae type b, Streptococcus pneumoniae, Neisseria
meningitidis and Salmonella typhi have been shown to
inhibit complement-mediated and phagocytic actions,
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thereby preventing initial control of infection [7,8].
Antibody to these CPs promote clearance of the orga-
nisms. Because the CPs of these bacteria are used for
diagnosis and prevention of diseases caused by these
pathogens, we evaluated the Mtb CPs as potential diag-
nostic reagents or vaccines for TB. This pilot study
assessed antibody responses to the two CPs of Mtb
among immunocompetent subjects who were stratified
according to their history of infection with and/or
disease caused by Mtb.
Methods
Subjects
Male and female subjects ≥ 18 years old (Table 1) were
recruited from the Texas Medical Center and from the
Harris County Hospital District in Houston, TX between
March 1999 and October of 1999. Informed consent was
obtained from each participant in accordance with pro-
tocols approved by the Institutional Review Board for
Human Subject Research for Baylor College of Medicine
& Affiliated Hospitals. Review of history of exposure to
or infection with Mtb, current medications, and poten-
tial immunosuppressive conditions was conducted by
clinicians with expertise in pulmonary medicine (RWA)
or infectious diseases (WAK). Medical records were
reviewed to document diagnoses, treatment and tuber-
culin skin testing results, as appropriate. All patients
with active TB were tested for antibodies to HIV-1: those
with no history of active TB were required to have a
negative HIV-1 serum antibody assay within a year of
blood collection. Subjects who had evidence of HIV-1
infection, immunosuppression or a history of BCG vac-
cination were excluded.
Clinical procedures
Enrolled subjects provided a 20 mL blood sample col-
lected from an arm vein. In addition, one subject with
active TB underwent plasmapheresis for collection of
plasma for assay standardization. Up to 11 subjects were
enrolled into each of the following groups corresponding
to the standard international classification of TB [9]:
Group 0 No history/evidence of TB or recent exposure
to TB and negative PPD (PPD-negative);
Group I Exposed to TB but no evidence of infection
(contact of a case, or exposed);
Group 2 TB infection (positive PPD) but no disease
(i.e., latent TB);
Group 3 Active TB;
Group 4 History of active TB with no current disease
(previously documented active TB).
Polysaccharides
The two polysaccharides were purified from a 70% ethanol
precipitate of a liquid culture of Mtb strain MT29248.
The precipitates were suspended in 0.02 M potassium
phosphate, pH 7.4, stirred 2 hours, spun down and the
supernatant passed through a DEAE column equilibrated
in the same buffer. The non-retarded fraction was concen-
trated, passed through a CL-4B Sepharose column and
the major peak, composed of Glu, freeze-dried. The later
eluant fractions were dialyzed against H2O, freeze dried
and passed through a CL-6B Sepharose column. The
single peak in this eluate, composed of AM, was dialyzed
and freeze-dried. Both CPs contained <1% protein and
nucleic acids [10].
ELISA
Serum anti-Glu or anti-AM levels were measured
by ELISA during year 2000 [11]. Nunc plates (PGC,
Frederick, MD) were coated with 100 μL of 10 μg/mL
Glu or AM in PBS. Mouse monoclonal anti-human
IgG, IgM, or IgA antibodies (IgG HP6043, IgM
HP6084, IgA HP6107; Centers for Disease Control
and Prevention) were used. Alkaline phosphatase-
labeled polyclonal rat-anti mouse was the 2nd anti-
body (Jackson Immuno Research Lab, Inc). A patient’s
plasma obtained by plasmapheresis was used as
the standard for the 3 isotypes The isotype-specific
concentrations of anti GLU and anti AM in that
plasma were assigned by ELISA in comparison to
purified IgG, IgM and IgA of known concentrations,
as described [12].
Statistical analyses
Unexposed, PPD-negative subjects (group 0) were con-
sidered the reference control group for statistical eva-
luations of serum antibody levels against the two
polysaccharides. Data were not normally distributed, so
non-parametric statistical analyses were performed.
Median antibody levels between groups were compared
using a Kruskall-Wallis (KW) test, and when significant
differences were identified, post- hoc comparisons of
other groups to group 0 were performed using Dunn’s
post hoc test corrected for multiple comparisons. P values
≤ 0.05 were considered significant.
Table 1 Characterization of enrolled subjects
TB Class Number Gender
(F:M)
Mean age in Race/Ethnicity
Years (SD)* (C:AA:H:A)
0 11 6:5 44.9 (10) 4:4:3:0
1 11 7:4 37.6 (11.2) 3:5:3:0
2 11 6:5 43.6 (10) 4:4:2:1
3 10 4:6 45.9 (14.3) 3:3:4:0
4 9 1:8 43.0 (4.8) 1:6:1:1
Abbreviations: F Female, M Male, C Caucasian, AA African-American,
H Hispanic, A Asian.
* p=NS between groups; ANOVA.




Fifty-two eligible subjects were enrolled (Table 1). The
mean age, sex and race/ethnicity distributions were similar
among the groups, with the exception of the group with a
history of treated TB, who were mostly African-American
males. Among 22 subjects who had no history of TB
exposure or infection (groups 0 and 1), 21 had a negative
PPD documented within 1 calendar year of enrollment, as
most of these subjects were employees of institutions
where annual skin testing is required. Among subjects
with latent TB (PPD+), the date of the positive PPD
ranged from 1959 (retested positive subsequent to sample
donation) to 1998, with a mean of 8 years since having a
positive test (range=1-19 years). Most of these subjects
worked in healthcare settings. Among patients with active
TB, the most common diagnosis was pulmonary TB
(9/10); the remaining subject had a mediastinal mass with
necrotizing granulomas. The mean time between diagno-
sis of TB and collection of the blood sample was 3 months
(range <0.5 to 12 months). Among 9 subjects with past
TB, 7 had completed therapy a mean of 3 years prior to
sample collection (range=<1 year to 5 years); one subjects
had completed therapy in Viet Nam at least 1 year before;
and the date of treatment was unknown for 1 subject.
Seven had been treated for pulmonary TB; one had
treated genitourinary TB, and one had been treated for
pleural disease.
Serologic
Antibodies to both polysaccharides were detectable in all
groups (Table 2 and Figure 1). There were no differences
in IgM antibody levels among the five groups for either
polysaccharide (p>0.25 for both AM and Glu; KW test).
There were, however, significant differences between the
groups for IgA and IgG levels to AM (p=0.010 and
0.001, respectively, KW test) and for IgA antibody levels
to Glu (p=0.005). Median IgG levels against Glu were not
significantly different between the five groups (p=0.08,
KW test). Although there was an overlap in the distribu-
tion of antibody levels between all groups, the median IgA
antibody levels to AM and Glu and the median IgG anti-
body levels to AM in subjects with previously documented
active TB were higher than unexposed subjects with a
negative PPD (p≤0.05 for all comparisons, Dunn’s post
hoc test). Similarly, for subjects with active TB, the median
levels of IgG anti AM test and IgA anti Glu were higher
than levels in unexposed subjects with a negative PPD
(group 0; p<0.05; Dunn’s pos hoc test). Median IgG
anti-Glu levels in Groups latent, active TB or previously
documented active TB were higher than in unexposed
PPD-negative subjects, but the differences were not sig-
nificant. Of note, the median IgG anti-Glu of subjects
with previously documented active TB (43.4) was 7
times higher than that of unexposed subjects who were
PPD-negative (6.3).
Discussion
Serum antibodies of the three major isotypes to two CPs
of Mtb in HIV-negative adults stratified according to
their tuberculosis status were measured by ELISA with
purified antigens. Antibodies to both polysaccharides
were detectable in all groups. Importantly, the Ig A anti-
Glu levels were significantly higher in the active and
treated TB groups compared to unexposed subjects who
were PPD-negative. Antibodies against AM demon-
strated a similar pattern, with the exception that IgG
anti-AM was higher in subjects with active TB or previ-
ously documented active TB, and the IgA anti-AM was
higher in subjects with previously documented active TB
Table 2 Median serum antibody levels (range) against capsular polysaccharides of Mycobacterium tuberculosis
(arabinomannan and glucan) according to TB class
TB Class Arabinomannan (μg/mL) Glucan (μg/mL)
IgM IgAa IgGa IgM IgAa IgG
0 8.6 3.3 163 7.9 0.7 6.3
(2.98–21.7) (1.05–11.1) (11.5–262) (1.4–21.0) (0.01–2.6) (0.12–38.5)
1 9.2 2.2 184 7.8 0.7 8.3
(1.5–45.7) (1.0–10.1) (81.4–4262) (1.6–26.7) (0.3–5.6) (1.0–137)
2 7.1 8.2 271 10.9 1.2 19.2
(4.1–55.7) (2.0–135) (154–1222) (1.0–18.4) (0.6–5.3) (2.2–48.4)
3 7.4 7.7 1181b 5.5 3.3b 23.3
(1.0–42.3) (2.2–42.9) (89.3–4227) (1.9–32.7) (1.5–38.5) (3.2–464)
4 8.9 11.5b 524b 10.7 5.2b 43.4
(3.1–30.5) (3.1–24.6) (189–1301) (2.0–62.3) (0.3–16.9) (0.4–240)
a p≤0.01, Kruskal–Wallis test (with group 0 as control group).
b p<0.05; Dunn’s post–hoc test adjusted for multiple comparisons.
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when compared with unexposed, PPD-negative subjects.
Serum IgG anti-Glu levels were higher in groups with
active TB or previously documented active TB than in a
group of unexposed, PPD-negative subjects, but the
differences were not significant. Thus, with this small
number of subjects, groups of patients who had active
or treated disease could be identified by the level of anti-
bodies to these two CPs. These data suggest that assays
based on antibody responses to the CPs of Mtb may be
of value for the serodiagnosis of TB.
What could be the origin of CP antibodies in unex-
posed, PPD-negative people? Similar to other capsulated
pathogens, cross-reactive anti-polysaccharide antibodies
were probably generated by exposure to environmental
mycobacteria or non-pathogenic enteric or pulmonary
bacteria [13-15]. In fact, we have previously shown that
the development of low level humoral immune re-
sponses to Mycobacterium avium sonic extracts and
mycobacterial LAM in children correlates with increa-
sing age, and by 18 years of age many individuals were
Figure 1 Panel A shows antibody titers against glucan and panel B shows antibody titers against arabinomannan. KW is Kruskal-Wallis
and significant P values are indicated for across group comparisons. Significant results for Dunn’s post-hoc analysis between groups are indicated
by asterisks (within a test, groups with the same number of asterisks are significantly [p<0.05] different from each other). Group 0 is not infected
and not exposed; group 1 is exposed, not infected; group 2 is latent tuberculosis; group 3 is active tuberculosis; and group 4 is previously
documented active tuberculosis without evidence of current disease.
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seroreactive to mycobacterial antigens [16]. This could
explain the levels observed in the adults with no history
or evidence of TB or of exposure to Mtb. The presence
of pre-existing anti-CP antibodies could confound use of
this method in TB diagnostics in areas with high expo-
sure to environmental mycobacteria or in countries
where BCG vaccination is routine.
The role of antibodies in the pathogenesis of tuber-
culosis and protection against Mtb infections is contro-
versial. Further, the impact of specific antibody isotypes
on TB infections is uncertain. The role of serum anti-
CPs is under study, but there are accumulating data that
this immune component may be protective [4,17-22].
The capsule of Mtb has been shown to limit the associ-
ation of the organism with macrophages [21]. The
antiphagocytic nature of the capsule is similar to that of
other encapsulated organisms. Antibody to the CPs of
Mtb may therefore enhance the uptake of organisms. A
protein-conjugate vaccine containing AM has been
shown to reduce the mycobacterial burden in vaccinated
mice [4]. Likewise, administration of a monoclonal anti-
body to the AM moiety of lipoarabinomannan to mice
resulted in a dose-dependent reduction in splenic and
lung bacterial loads and promoted survival [18]. Inter-
estingly, most of the protective antibodies have an IgG
isotype. Our data regarding the serum antibody re-
sponses of healthy and Mtb-infected adults to the two
Mtb CPs provide information that may be useful in
evaluating the effect of CP-based vaccines. Clearly, the
pre-existing anti-CP antibody titers should be assessed
in volunteers prior to immunization with TB CP vac-
cines. In initial studies of the safety and immunogenicity
of these vaccines, volunteers should have low anti-CP
antibody titers to preclude pre-existing antibody inter-
ference with the analysis of vaccine activity. Subsequent
studies could evaluate whether volunteers with high
pre-existing anti-CP antibody levels could be boosted by
vaccination.
Conclusions
In summary, serum antibody levels against surface CPs
were shown to be higher among subjects with active or
treated tuberculosis. Similar results showing higher AM
IgG antibody levels in TB patients than in controls, and
higher in TB-HIV negative than in TB-HIV positive pa-
tients, were published recently [23]. Our data provide
quantitative evidence that disease caused by Mtb elicits
an immune response to the CPs. The small sample sizes
in our study may have interfered with the ability to
detect significant differences among groups for several
isotypes of antibody. Expanded studies of defined popu-
lations are indicated in order to assess the utility of these
assays for epidemiologic and/or clinical purposes.
Competing interests
None of the living authors have competing interests; no competing interests
are known for RWA.
Authors’ contributions
WAK: Study design; data acquisition, analyses and interpretation; manuscript
preparation and revision. ZDD: Antibody purification and detection assay;
study design; manuscript preparation and revision. RWA: Study design; data
acquisition. RLA: Data analyses and interpretation; manuscript preparation
and revision. SM: Antigen preparation; manuscript review (Internal funding).
RS: Supervision of antibody purification and detection assay; study
conception and design; data interpretation; manuscript preparation, revision
and approval. JBR: Supervision of antibody purification and detection assay;
study conception and design; data interpretation; manuscript pr eparation,
revision and approval. All authors (with the exception of Dr. Awe) read and
approved the final manuscript.
Authors’ information
Dr. Rachel Schneerson, Dr. John Robbins and Dr. ZhongDong Dai these
authors are retired.
Acknowledgements
This study was supported by the Intramural Research Program of the Eunice
Kennedy Shriver National Institute of Child Health and Human Development,
National Institutes of Health and Food and Drug Administration/Center for
Biologics Evaluation and Research internal funds.
The authors gratefully acknowledge the participation of our subjects; the
contributions of Nanette Bond, PA-C, Diane Nino, and the personnel who
assisted in the conduct of the study at the Ben Taub General Hospital TB
clinic; and Li Zhang for technical assistance.
Author details
1Departments of Molecular Virology & Microbiology and Medicine, Baylor
College of Medicine, Houston, TX, USA. 2Program on Developmental and
Molecular Immunity, Eunice Schriver Kennedy Institute of Child Health and
Human Development, NIH, Bethesda, MD 20852, USA. 3Ben Taub General
Hospital, Houston, TX, USA. 4CBER, Food and Drug Administration, Houston,
TX, USA.
Received: 6 August 2012 Accepted: 29 May 2013
Published: 19 June 2013
References
1. WHO tuberculosis fact sheet No.104; 2012. http://www.who.int/mediacentre/
factsheets/fs104/en/.
2. Coldirz GA, Brewer TF, Berkley CS, Wilson ME, Burdick E, Fineberg HV,
Mosteller F: Efficacy of BCG vaccine in the prevention of tuberculosis.
JAMA 1994, 271:698–702.
3. Daffé M, Etienne G: The capsule of Mycobacterium tuberculosis and its
implications for pathogenicity. Tuber Lung Dis 1999, 79:153–169.
4. Glatman-Freedman A, Casadevall A, Dai Z, Jacobs WR Jr, Li A, Morris SL,
Navoa JA, Piperdi S, Robbins JB, Schneerson R, Schwebach JR, Shapiro M:
Antigenic evidence of prevalence and diversity of Mycobacterium
tuberculosis arabinomannan. J Clin Microbiol 2004, 42:3225–3231.
5. Ortalo-Magné A, Dupont MA, Lemassu A, Andersen AB, Gounon P, Daffé M:
Molecular composition of the outermost capsular material of the
tubercle bacillus. Microbiol 1995, 141:1609–1620.
6. Schwebach JR, Glatman-Freedman A, Gunether-Cummins L, Dai Z, Robbins
JB, Schneerson R, Casadevall A: Gucan is a component of the
Mycobacterium tuberculosis surface that is expressed in vitro and in vivo.
Infect Immun 2002, 70:2566–2575.
7. Marchant CD, Kumar ML: Immunizations. In Pediatric infectious diseases:
principles and practices. Edited by Jenson HB, Baltimore RS. Philadelphia PA:
The WB Saunders Co; 2002:232–262.
8. Trotter CL, Ramsay ME, Kazmarski EB: Meningococcal serogroup C
conjugate vaccination in England and Wales: coverage and initial impact
of the campaign. Commun Dis Publ Health 2002, 5:220–225.
9. American Thoracic Society: Diagnostic standards and classification of
tuberculosis in adults and children. Am J Resp Crit Care Med 2000,
161:1376–1395.
Keitel et al. BMC Infectious Diseases 2013, 13:276 Page 5 of 6
http://www.biomedcentral.com/1471-2334/13/276
10. World Health Organization Expert Committee on Biological Standardization:
Technical research series 610. Geneva 1, Switzerland: WHO; 1977.
11. Vann WF, Sutton A, Schneerson R: Enzyme-linked immunosorbent assay.
Methods Enzymol 1990, 184:537–541.
12. Claesson B, Trollfors B, Lagergard T, Taranger J, Bryla D, Otterman G,
Cramton T, Yang Y-H, Reimer CB, Robbins JB, Schneerson R: Clinical and
immunologic responses to the capsular polysaccharide of Haemophilus
influenzae type b alone or conjugated to tetanus toxoid in 18- to
23-month-old children. J Pediatr 1988, 112:695–702.
13. Lemassu A, Ortalo-Magné A, Bardou F, Silva G, Kandéelle MA, Daffé M:
Extracellular and surface-exposed polysaccharide of non-Tuberculous
mycobacteria. Microbiol 1996, 142:1513–1520.
14. Rastogi N, Fréhel C, David HL: Triple-layered structure of mycobacterial
cell wall: evidence of the existence of a polysaccharide-rich outer layer
in 18 mycobacterial species. Curr Microbiol 1986, 13:237–252.
15. Sell SHW, Karzon DT: Conference on Antigen-Antibody Systems,
Epidemiology, and Immunoprophylaxis: cross-reacting antigens of
enteric bacteria as an antigenic source for "natural" antibodies to
bacteria causing meningitis. In Hemophilus influenzae: [proceedings of a
Conference on antigen-antibody systems, epidemiology, and
immunoprophylaxis, April 24-25, 1972, Nashville, Tenn, sponsored by Vanderbilt
University and the Department of Pediatrics of the Vanderbilt School of
Medicine]. Nashville: Vanderbilt University Press; 1973:269–280.
16. Fairchok M, Rouse J, Morris S: Age-dependent humoral responses of children
to mycobacterial antigens. Clin Diag Lab Immunol 1995, 2:443–447.
17. Costello AM, Kumar A, Narayan V, Akbar MS, Ahmed S, Abon-Zeid C, Rook
CA, Stanford J, Moreno C: Does antibody to mycobacterial antigens,
including lipoarabinomann, limit dissemination in childhood
tuberculosis? Trans Roy Soc Trop Med Hyg 1992, 86:686–692.
18. Hamasur B, Haile M, Pawlowski A, Schröder U, Williams A, Hatch G, Hall G,
Marsh P, Källenius G, Svenson SB: Mycobacterium tuberculosis
arabinomannan-protein conjugates protect against tuberculosis. Vaccine
2003, 21:4081–4093.
19. Sambou T, Dinadayala P, Stadthagen G, Barilone N, Bordat Y, Constant P,
Levillain F, Neyrolles O, Gicquel B, Lemassu A, Daffé A, Jackson M: Capsular
glucan and intracellular glycogen of Mycobacterium tuberculosis:
biosynthesis and impact on the persistence in mice. Mol Microbiol 2008,
70:762–764.
20. Seibert FB, Miller EE, Buseman U, Seibert MV, Soto-Figueroa E, Fry L: The
significance of antibodies to tuberculoprotein and polysaccharide in
resistance to tuberculosis; interference with antibodies by these
antigens. Am Rev Tuberc 1956, 73:547–562.
21. Stokes RW, Norris-Jones R, Brooks DE, Beveridge TJ, Doxsee D, Thorson LM:
The glycan-rich outer layer of the cell wall of mycobacterium
tuberculosis acts as an antiphagocytic capsule limiting the association of
the bacterium with macrophages. Infect Immun 2004, 72:5676–5686.
22. Teitelbaum R, Glatman-Freedman A, Chen B, Robbins JB, Unanue E,
Casadevall A, Bloom BR: A MoAb recognizing a surface antigen of
Mycobacterium tuberculosis enhances host survival. Proc Natl Acad Sci USA
1998, 95:15688–15693.
23. Yu S, Prados-Rosales R, Jenny-Avital ER, Sosa K, Casadevall A, Achkar JM:
Comparative evaluation of antibody profiles to Mycobacterial capsular
polysaccharides in tuberculosis patients and controls stratified by HIV
status. Clin Vaccine Immunol 2012, 19:198–208.
doi:10.1186/1471-2334-13-276
Cite this article as: Keitel et al.: Effects of infection and disease with
Mycobacterium tuberculosis on serum antibody to glucan and
arabinomannan: two surface polysaccharides of this pathogen. BMC
Infectious Diseases 2013 13:276.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Keitel et al. BMC Infectious Diseases 2013, 13:276 Page 6 of 6
http://www.biomedcentral.com/1471-2334/13/276
